设为首页 加入收藏

TOP

STEGLUJAN(ertugliflozin and sitagliptin)tablets(二十五)
2018-06-21 11:17:27 来源: 作者: 【 】 浏览:19748次 评论:0
m a Factorial Study with Ertugliflozin and Sitagliptin as Add-on Combination Therapy with Metformin Compared to Individual Components Alone* 
Sitagliptin 100 mg
Ertugliflozin 5 mg
Ertugliflozin 15 mg
Ertugliflozin 5 mg +Sitagliptin 100 mg
Ertugliflozin 15 mg + Sitagliptin 100 mg
* N includes all randomized and treated patients with a baseline measurement of the outcome variable. At Week 26 the primary HbA1c endpoint was missing for 13%, 10%, 11% , 11%, and 12% of patients and during the trial rescue medication was initiated by 6%, 6%, 3%, 2%, and 0% of patients randomized to sitagliptin, ertugliflozin 5 mg, ertugliflozin 15 mg, ertugliflozin 5 mg + sitagliptin, and ertugliflozin 15 mg + sitagliptin, respectively. Missing Week 26 measurements were imputed using multiple imputation with a mean equal to the baseline value of the patient. Results included measurements collected after initiation of rescue medication. For those subjects who did not receive rescue medication and had values measured at 26 weeks, the mean change from baseline for HbA1c was -1.1%, -1.1%, -1.1%, -1.5% and -1.6% for sitagliptin, ertugliflozin 5 mg, ertugliflozin 15 mg, ertugliflozin 5 mg + sitagliptin, and ertugliflozin 15 mg + sitagliptin, respectively. † Intent-to-treat analysis using ANCOVA adjusted for baseline value and baseline eGFR. ‡ p<0.001 compared to control group. § p<0.03 compared to control group.  
HbA1c (%) N = 242 N = 244 N = 247 N = 237 N = 241 
  Baseline (mean) 8.5 8.6 8.6 8.6 8.6 
  Change from baseline (LS mean†) -1.0 -1.0 -1.0 -1.4 -1.4 
  Difference from      
    Sitagliptin    -0.4‡ (-0.6, -0.2) -0.4‡ (-0.5, -0.2) 
    Ertugliflozin 5 mg    -0.4‡ (-0.5, -0.2)  
    Ertugliflozin 15 mg     -0.4‡ (-0.6, -0.2) 
  (LS mean†, 95% CI)      
Patients [N (%)] with HbA1c <7% 93 (38.5) 72 (29.3) 83 (33.7) 126 (53.3) 123 (50.9) 
FPG (mg/dL) N = 246 N = 250 N = 247 N = 240 N = 241 
  Baseline (mean) 177.4 184.1 179.5 183.8 177.2 
  Change from baseline (LS mean†) -24.3 -34.0 -34.6 -41.1 -44.3 
  Difference from      
    Sitagliptin    -16.8‡ (-23.2, -10.4) -20.0‡ (-26.4, -13.6) 
    Ertugliflozin 5 mg    -7.0§ (-13.3, -0.7)  
    Ertugliflozin 15 mg     -9.8§ (-16.1, -3.4) 
  (LS mean†, 95% CI)      
The mean baseline body weight was 89.8 kg, 88.6 kg, 88.0 kg, 89.5 kg, and 87.5 kg in the sitagliptin 100 mg, ertugliflozin 5 mg, ertugliflozin15 mg, ertugliflozin 5 mg + sitagliptin 100 mg, and ertugliflozin 15 mg + sitagliptin 100 mg groups, respectively. The mean changes from baseline to Week 26 were -0.4 kg, -2.6 kg, -3.4 kg, -2.4 kg, and -2.7 kg in the sitagliptin 100 mg, ertugliflozin 5 mg, ertugliflozin 15 mg, ertugliflozin 5 mg + sitagliptin 100 mg, and ertugliflozin 15 mg + sitagliptin 100 mg groups, respectively. The difference from sitagliptin 100 mg (95% CI) for ertugliflozin 5 mg + sitagliptin 100 mg was -1.9 kg (-2.6, -1.3) and for ertugliflozin 15 mg + sitagliptin 100 mg was -2.3 kg (-3.0, -1.6
以下是“全球医药”详细资料
Tags: 责任编辑:admin
首页 上一页 22 23 24 25 26 27 28 下一页 尾页 25/37/37
】【打印繁体】【投稿】【收藏】 【推荐】【举报】【评论】 【关闭】 【返回顶部
分享到QQ空间
分享到: 
上一篇SEGLUROMET(ertugliflozin and me.. 下一篇STEGLATRO(ertugliflozin tablets)

相关栏目

最新文章

图片主题

热门文章

推荐文章

相关文章

广告位